The approach was first to vaccinate mice against DNP, an innocuous hapten, establish tumors in the mice, and then treat the vaccinated tumor-bearing mice with a VEGF or OPN aptamer–DNP conjugate that target the DNP hapten to the tumor and attracts the preformed polyclonal DNP antibodies (Fig.1). This evidence concerns the gene VEGFA and neoplasm.